Hemera Biosciences   Report issue

For profit Phase 1 Phase 2
Founded: Newton MA United States (2010)

Organization Overview

First Clinical Trial
2017
NCT03144999
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Hemera Biosciences

Active Ingredients

Drugs in Phase 2 Trials (1)

aavcagscd59 (3 trials)

Drugs in Phase 1 Trials (4)

aflibercept (zaltrap) (1 trial)

bevacizumab (avastin) (1 trial)

prednisolone (hydeltra) (1 trial)

ranibizumab (lucentis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 2)

Geographic Atrophy (Phase 2)

Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 5